Cargando…

Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus – New Findings on SGLT2 Inhibitors

Detalles Bibliográficos
Autor principal:	Brinkmann, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320760/ https://www.ncbi.nlm.nih.gov/pubmed/34335470 http://dx.doi.org/10.3389/fendo.2021.694099

Ejemplares similares

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials
por: Jiang, Yu, et al.
Publicado: (2022)

Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
por: Wei, Qiong, et al.
Publicado: (2021)

The impact of SGLT2 inhibitors on αKlotho in renal MDCK and HK-2 cells
por: Wolf, Lisa, et al.
Publicado: (2023)

GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
por: Yan, Hongle, et al.
Publicado: (2022)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
por: Donnan, Jennifer R, et al.
Publicado: (2019)

Is intake of fruit juice useful in exercise-induced hypoglycemia prevention in individuals with type 1 diabetes mellitus?
por: Valder, Sarah, et al.
Publicado: (2022)

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
por: Chen, Xiutian, et al.
Publicado: (2023)

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
por: Shyangdan, Deepson S, et al.
Publicado: (2016)

Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Case Report and Review of Literature
por: Aggarwal, Ankita, et al.
Publicado: (2020)

Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis
por: Yang, Liu, et al.
Publicado: (2022)

Exercise, type 1 diabetes mellitus and blood glucose: The implications of exercise timing
por: Fitzpatrick, Ross, et al.
Publicado: (2022)

Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
por: Maradia, Jay, et al.
Publicado: (2023)

SGLT2i: beyond the glucose-lowering effect
por: Ni, Lihua, et al.
Publicado: (2020)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
por: Nagayama, Ayako, et al.
Publicado: (2021)

Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis
por: Zhou, Peipei, et al.
Publicado: (2023)

Comprehensive review of SGLT2 inhibitors’ efficacy through their diuretic mode of action in diabetic patients
por: Lam-Chung, Cesar Ernesto
Publicado: (2023)

Association of subclass distribution of insulin antibody with glucose control in insulin-treated type 2 diabetes mellitus: a retrospective observational study
por: Chen, Shuang, et al.
Publicado: (2023)

Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
por: Yang, Yinqiu, et al.
Publicado: (2020)

Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes
por: Jain, Rajesh, et al.
Publicado: (2022)

A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Patel, Khyati, et al.
Publicado: (2022)

A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022)

Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2018)

Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
por: Zhou, Bin, et al.
Publicado: (2022)

Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
por: Maki, Toshinobu, et al.
Publicado: (2019)

Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
por: Kim, Hwi Seung, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
por: Cignarelli, Angelo, et al.
Publicado: (2022)

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
por: Clar, Christine, et al.
Publicado: (2012)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus
por: Saito, Masako, et al.
Publicado: (2020)

Fournier’s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy
por: Chowdhury, Tutul, et al.
Publicado: (2022)

Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis
por: Chung, Mu-Chi, et al.
Publicado: (2022)

ARHGAP21 Acts as an Inhibitor of the Glucose-Stimulated Insulin Secretion Process
por: Ferreira, Sandra M., et al.
Publicado: (2020)

Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
por: Zhang, Sha, et al.
Publicado: (2023)

The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture
por: Dong, Bingzi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k5l6et3iqke9l5tdrdkj6904pu